TAXOTERE Drug Patent Profile

Which patents cover Taxotere, and what generic alternatives are available?

Taxotere is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in TAXOTERE is docetaxel. There are forty-one drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the docetaxel profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Taxotere

A generic version of TAXOTERE was approved as docetaxel by HOSPIRA INC on March 8^th, 2011.

Summary for TAXOTERE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	80
Clinical Trials:	772
Patent Applications:	6,676
Drug Prices:	Drug price information for TAXOTERE
What excipients (inactive ingredients) are in TAXOTERE?	TAXOTERE excipients list
DailyMed Link:	TAXOTERE at DailyMed

See drug prices for TAXOTERE

Recent Clinical Trials for TAXOTERE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Medical University of South Carolina	PHASE2
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	PHASE2
Qilu Pharmaceutical (Hainan) Co., Ltd.	PHASE1

See all TAXOTERE clinical trials

Paragraph IV (Patent) Challenges for TAXOTERE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TAXOTERE	Injection	docetaxel	40 mg/mL, 0.5 mL and 2 mL vials	020449	1	2009-06-30

US Patents and Regulatory Information for TAXOTERE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-003	Aug 3, 2010		DISCN	Yes	No
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-005	Apr 13, 2012	AP	RX	Yes	No
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-001	May 14, 1996		DISCN	Yes	No
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-004	Aug 2, 2010		DISCN	Yes	No

Expired US Patents for TAXOTERE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	TAXOTERE	docetaxel	INJECTABLE;INJECTION	020449-001	May 14, 1996

EU/EMA Drug Approvals for TAXOTERE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Accord Healthcare S.L.U.	Docetaxel Accord	docetaxel	EMEA/H/C/002539Breast cancerDocetaxel Accord in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Accord in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Accord monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Accord in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Accord in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Accord is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Accord in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Accord in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Accord in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Authorised	yes	no	no	2012-05-22
Teva B.V.	Docetaxel Teva	docetaxel	EMEA/H/C/001107Breast cancerDocetaxel Teva in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Teva in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Teva monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy.Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Teva in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Teva in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Teva is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Teva in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Teva in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Teva in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Teva in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Withdrawn	yes	no	no	2010-01-26
Sanofi Mature IP	Taxotere	docetaxel	EMEA/H/C/000073Breast cancerTaxotere in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Taxotere in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Taxotere monotherapy is indicated for the treatment of patients with locally advanced ormetastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Taxotere in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Taxotere in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerTaxotere is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Taxotere in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerTaxotere in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinomaTaxotere in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerTaxotere in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Authorised	no	no	no	1995-11-27
Fresenius Kabi Deutschland GmbH	Docetaxel Kabi	docetaxel	EMEA/H/C/002325Breast cancerDocetaxel Kabi in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Kabi in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Kabi monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Kabi in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Kabi in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Kabi is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Kabi in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Kabi in combination with prednisone or prednisolone is indicated for the treatment of patients with castration-resistant metastatic prostate cancer.Docetaxel Kabi in combination with androgen-deprivation therapy (ADT), with or without prednisone or prednisolone, is indicated for the treatment of patients with metastatic hormone-sensitive prostate cancer.Gastric adenocarcinomaDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Kabi in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Authorised	yes	no	no	2012-05-22
Zentiva k.s.	Docetaxel Zentiva (previously Docetaxel Winthrop)	docetaxel	EMEA/H/C/000808Breast cancerDocetaxel Winthrop in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Docetaxel Winthrop in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Docetaxel Winthrop monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Docetaxel Winthrop in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress HER2 and who previously have not received chemotherapy for metastatic disease.Docetaxel Winthrop in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small-cell lung cancerDocetaxel Winthrop is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer after failure of prior chemotherapy.Docetaxel Winthrop in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small-cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancerDocetaxel Winthrop in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer.Gastric adenocarcinomaDocetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancerDocetaxel Winthrop in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Withdrawn	no	no	no	2007-04-20
Hospira UK Limited	Taxespira (previously Docetaxel Hospira UK Limited )	docetaxel	EMEA/H/C/003925Breast cancerTaxespira in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with:operable node-positive breast cancer;operable node-negative breast cancer.For patients with operable node-negative breast cancer, adjuvant treatment should be restricted to patients eligible to receive chemotherapy according to internationally established criteria for primary therapy of early breast cancer.Taxespira in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition.Taxespira monotherapy is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic therapy. Previous chemotherapy should have included an anthracycline or an alkylating agent.Taxespira combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours over express HER2 and who previously have not received chemotherapy for metastatic disease.Taxespira in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy. Previous therapy should have included an anthracycline.Non-small cell lung cancer Taxespira indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior chemotherapy.Taxespira in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer, in patients who have not previously received chemotherapy for this condition.Prostate cancer Taxespira in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.Gastric adenocarcinoma Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the treatment of patients with metastatic gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for metastatic disease.Head and neck cancer Taxespira in combination with cisplatin and 5-fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck.	Withdrawn	yes	no	no	2015-08-28
Mylan S.A.S.	Docetaxel Mylan	docetaxel	EMEA/H/C/002317Treatment of breast cancer, special forms of lung cancer (non-small-cell lung cancer), prostate cancer, gastric cancer, or head and neck cancer.	Withdrawn	yes	no	no	2012-01-31

International Patents for TAXOTERE

See the table below for patents covering TAXOTERE around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	49962
Australia	591309
Australia	7567787
Canada	1278304	DERIVES DU TAXOL, LEUR PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT (DERIVES DU TAXOL, LEUR PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT)
Germany	3761562
European Patent Office	0253738	TAXOL DERIVATIVES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
France	2601675	DERIVES DU TAXOL, LEUR PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT

Supplementary Protection Certificates for TAXOTERE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0253738	96C0009	Belgium		PRODUCT NAME: CONCENTRE A 85 % D'OMEGA POLYINSATURES; QUANTITE CORRESPONDANT A :; ESTERS ETHYLIQUES D'ACIDE EICOSAPENTAENOIQUE (EPA) ET D'ACIDE DOCOSAHEXAENOIQUE (DHA); ALPHA TOCOPHEROL; NAT. REGISTRATION NO/DATE: NL 20819 19951002; FIRST REGISTRATION:
0253738	C960002	Netherlands		PRODUCT NAME: DOCETAXEL, DESGEWENST IN DE VORM VAN EEN TRIHYDRAAT; REGISTRATION NO/DATE: EU/1/95/002/001 - EU/1/95/002/002 19951127
1667986	92172	Luxembourg		PRODUCT NAME: SOLVAT ACETONIQUE DU CABAZITAXEL, OU DESIGNE SOLVAT ACETONIQUE DU DIMETHOXY DOCETAXEL OU SOLVAT ACETONIQUE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2A-BENZOYLOXY-5BETA,20-EPOXY-1-HYDROXY-7BETA,10A-DIMETHOXY-9-OXO-TAX-11-ENE-13A-YLE(ACETONATE DU CABAZITAXEL)
1667986	28/2013	Austria		PRODUCT NAME: DIMETHOXYDOCETAXEL-ACETONSOLVAT (CABAZITAXEL-ACETONSOLVAT); REGISTRATION NO/DATE: EU/1/11/676/001 20110317

TAXOTERE (docetaxel) Market Dynamics and Financial Trajectory: Pricing, Uptake, Competitive Erosion, and Patent/Exclusivity Pressure

Last updated: July 30, 2026

Taxotere’s market performance is driven by (1) steady demand in metastatic breast cancer and lung cancer, (2) rapid competitive substitution after patent/exclusivity falloffs, (3) chemotherapy protocol inclusion that supports baseline utilization, and (4) pricing pressure from multisource docetaxel brands and generics in the US and other markets. Financial trajectory has tracked the shift from originator-led revenue to a lower-price, generic-heavy commercial environment.

What is the commercial market landscape for Taxotere (docetaxel) and how has it changed over time?

Direct answer: Taxotere is a mature, small-molecule oncology chemotherapy with long-running clinical adoption. The market has moved from higher-priced originator dominance to broad generic penetration, with originator revenue under pressure as patent protection and reference product exclusivity eroded and cheaper suppliers expanded.

Which indications drive Taxotere demand

Taxotere’s prescribing base is anchored in oncology regimens that remain common in clinical practice:

• Metastatic breast cancer (including combination regimens)
• Non-small cell lung cancer
• Hormone-refractory prostate cancer (historically a major use case)
• Gastric adenocarcinoma and other solid tumors depending on label-era and region

Protocol persistence matters more than new-cycle product narratives because docetaxel’s role in established treatment pathways is durable.

What has been the competitive set

Taxotere’s competitive set has been dominated by:

• Multisource docetaxel products (brand-to-generic replacement)
• Generic docetaxel entry after approval and exclusivity windows
• Alternative cytotoxics and newer targeted regimens in the same lines of therapy

Docetaxel still competes on regimen value, not “innovation,” so price and supply reliability dominate once generic alternatives are on-formulary.

When does Taxotere lose exclusivity and what does that mean for future revenue?

Direct answer: Taxotere’s US originator exclusivity has already passed; the current revenue risk is primarily generic-driven price compression rather than imminent first-loss exclusivity.

Exclusivity framework that historically mattered

For an originator chemotherapy like docetaxel, revenue inflection typically follows:

• Primary patent expiry on the active ingredient and key formulations
• Loss of data exclusivity where applicable to specific filings
• Generic entry via abbreviated pathways after patent challenges and “paragraph IV” settlements (when they occur)

After these events, the market typically transitions quickly to lowest-price procurement, especially for infusion oncology drugs where acquisition costs can be a large fraction of pharmacy budgets.

How exclusivity loss translates into pricing

Once multiple suppliers are available:

• Average selling price trends down
• Net price further declines due to rebates, contracting, and hospital purchasing terms
• Volume growth is constrained because docetaxel demand is already embedded in existing protocols

For mature oncology drugs, the slope of revenue decline depends on how fast generic supply scales and how aggressively payers and group purchasing organizations switch.

What generic entry risks exist for Taxotere docetaxel in the US and how do Paragraph IV challenges affect timing?

Direct answer: Docetaxel’s generic entry risk is structurally lower than for newer drugs because the active ingredient market is already mature and suppliers are established. The major ongoing risk is replacement of remaining branded share by additional low-cost suppliers and litigation-driven supply constraints.

Paragraph IV dynamics that typically affect mature products

When patent challenges occur, the main variables are:

• Whether a court stays FDA approval or allows earlier launch
• Whether settlements permit an agreed “design-around” or launch date
• Whether formulation or method patents delay entry for specific dosage forms or manufacturing steps

Even if first originator exclusivity is gone, subsidiary patents can still delay certain “non-interchangeable” presentations. In practice, these delays usually shorten as the product becomes interchangeable and procurement standards tighten.

What is the Orange Book status of Taxotere and how many patents can block generics?

Direct answer: Taxotere’s Orange Book landscape reflects a mature asset with multiple listed patents and continued listings related to formulations and manufacturing/usage. Patent listings historically mattered most at the time of generic entry; today, they mostly affect narrow product form variants rather than halting general docetaxel competition.

Which patent categories tend to dominate in docetaxel assets

For infusion oncology drugs, listed patents often cluster in:

• Formulation (composition, stabilizers, concentration, lyophilized vs. liquid presentations)
• Manufacturing process (controls, impurity profiles, sterilization, reconstitution stability)
• Method-of-use (less common for widely entrenched chemotherapy regimens, but possible around specific regimen combinations)

The commercial consequence is typically limited. Once interchangeability is accepted and procurement targets “docetaxel” rather than “Taxotere,” generic substitution becomes the default.

How does Taxotere compare with competing docetaxel brands and generic docetaxel on price and market share?

Direct answer: Taxotere competes on historical brand recognition and supplier continuity, but generics generally win on net cost. For most health systems, docetaxel tendering shifts quickly once multiple FDA-approved alternatives are available.

What drives purchasing decisions

Hospital procurement for chemotherapy often follows:

• Acquisition cost and tender contracts
• Supply reliability and logistics for refrigerated or controlled handling items (where applicable)
• Therapeutic equivalence and interchangeability

For Taxotere, brand differentiation erodes when multiple suppliers offer equivalent dosing and acceptable stability.

Where Taxotere can retain share

Originator share can persist when:

• Certain contracted pathways prefer a specific branded product
• Switching barriers exist due to internal formulary decisions
• Patient-specific history and infusion protocol preferences favor a consistent supplier These effects tend to be local and contract-specific.

What formulation and delivery patents historically protected Taxotere and how do they affect current competition?

Direct answer: Taxotere’s formulation IP historically supported higher pricing and reduced generic pressure for specific presentations. Post-expiry, formulation patents typically do not stop generic docetaxel from competing on core interchangeability, but they can delay specific dosage strengths, packaging, or manufacturing variants.

Common formulation levers for infusion taxanes

For docetaxel products, formulation protection has historically included:

• Solubilizing system and excipient selection
• Concentration-specific stability and shelf life
• Reconstitution and infusion-time stability
• Impurity and degradation controls

For commercialization, generic manufacturers must meet product-specific quality attributes, and formulation and process requirements can create entry friction even after legal barriers fall.

What litigation and settlement history has shaped Taxotere’s financial trajectory?

Direct answer: Taxotere’s revenue path is shaped by historic patent challenges and settlement outcomes that determined when competing products could enter. In mature chemotherapy classes, litigation rarely stops long-term genericization; it mainly governs launch timing and whether supply is delayed for certain presentations.

How litigation impacts revenue even after patents expire

Even after broad patent expiry:

• Remaining litigation can delay “faster follower” entrants
• Settlements can delay launch of certain generic SKUs
• Courts can affect whether FDA-approved products can be marketed immediately

Those timing effects can create short bursts of competitive intensity or pockets of retention for originator revenue before broader price compression returns.

What is Taxotere’s FDA regulatory profile and does it change commercial timing?

Direct answer: Taxotere is an FDA-approved chemotherapy with long-established labeling. Regulatory timing affects new entrant marketing more than it affects ongoing demand. Commercial dynamics are therefore dominated by patent and pricing rather than by new regulatory milestones.

Pathway implications

• Generic approvals generally follow abbreviated regulatory pathways
• Interchangeability and labeling parity determine whether hospital formularies switch quickly
• Post-marketing requirements (if any) can affect timelines for new submissions and manufacturing changes

Once the product is established, regulatory events are more likely to be quality and manufacturing updates than new clinical expansions.

How does Taxotere’s revenue trajectory compare to other mature oncology chemotherapy drugs?

Direct answer: Taxotere follows the typical mature oncology pattern: stable baseline volume but declining unit economics once generic competition scales. Total revenue becomes more sensitive to market share loss than to growth in demand.

Common lifecycle pattern in cytotoxic oncology

• Early-to-mid lifecycle: branded share and higher net price
• Late lifecycle: brand share declines, net price compresses
• Post-generic saturation: price floors tighten; share moves toward suppliers with contracting strength

Taxotere’s trajectory aligns with that structure because docetaxel demand is protocol-driven and not easily replaced by a single alternative.

What commercial KPIs best track Taxotere’s financial trajectory now?

Direct answer: The most decision-relevant KPIs for a mature docetaxel franchise are contract-driven net price, US and ex-US share, and gross-to-net movement driven by rebates and channel mix. Volume is usually less volatile than pricing in a generic-heavy market.

Operational metrics

• US and international net sales by quarter
• ASP and net selling price trends
• Gross-to-net percentage changes from contracting
• Volume trends by major region and channel
• Manufacturer-level procurement shifts where multiple generic equivalents exist

Strategic metrics

• Formulary placement changes across major group purchasing organizations
• Tender wins and renewals at large hospital networks
• Supply stability disruptions that can force temporary reversion to preferred SKUs

Where is revenue exposure highest: US vs ex-US markets, and what risks dominate by region?

Direct answer: Revenue exposure is typically highest where generic penetration is incomplete or where contracting favors branded SKUs for specific protocols. Ex-US markets can remain more profitable longer where local patent enforcement, regulatory approvals, or market access timelines are slower.

Regional risk factors that affect net sales

• Local patent status and enforcement pace
• Approval/launch lead times for local generic manufacturers
• Pricing regulation or reimbursement controls
• Distribution channel structure and hospital procurement practices

Generic penetration timing drives the revenue cliff more than demand.

Key Takeaways

• Taxotere’s market dynamics are dominated by mature oncology demand and sustained protocol inclusion, with revenue primarily threatened by generic substitution and net price compression rather than by new exclusivity events.
• Competitive pressure increases as docetaxel supply broadens across brands and generics, shifting the market from differentiation to procurement economics.
• Patent and Orange Book listings historically governed launch timing and specific presentation entry, but the commercial market has largely transitioned to a low-price, multiparty equilibrium.
• Near-term financial trajectory is best tracked by net price (gross-to-net), formulary and contracting share, and the timing of additional low-cost launches rather than by clinical demand growth.

FAQs

1. How quickly does the market shift from Taxotere to generic docetaxel after generic approval?
   Typically fastest through hospital group purchasing contracts, where procurement standards move to the lowest net-cost interchangeable option once multiple equivalent suppliers are available.

2. Which Taxotere dosage forms usually face slower substitution risk?
   Any specific presentation tied to narrower formulation, concentration, or packaging features can experience slower uptake if procurement rules require tighter interchangeability criteria.

3. Does Taxotere still have revenue upside from new oncology regimens?
   For mature docetaxel, revenue upside is usually incremental and contract-dependent; the dominant lever remains net pricing and share retention amid generics.

4. What KPIs indicate whether a competitor’s generic entry will accelerate Taxotere revenue decline?
   Evidence of rapid formulary updates, tender award shifts, and widening multi-supplier competition usually signals faster net price erosion.

5. How do supply chain disruptions affect Taxotere’s commercial performance in a generic-heavy market?
   Short-term shortages in any supply channel can temporarily shift procurement back to available branded or specific generic SKUs, but the effect usually reverses when supply normalizes.

---

References

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
2. FDA. Drug Approval Package for TAXOTERE (docetaxel). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
3. FDA. Abbreviated New Drug Applications (ANDA). U.S. Food and Drug Administration. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda
4. FDA. Patent and Exclusivity for Drugs. U.S. Food and Drug Administration. https://www.fda.gov/drugs/patent-and-exclusivity-drugs

DrugChatter Q&A for TAXOTERE

Taxotere fda exclusivity end date?
Taxotere patent expiration?
Taxotere fda exclusivity expiration date?
Taxotere fda exclusivity date?
Taxotere patent expiration year?